title: Histone Acetylation Modifiers in the Pathogenesis of Alzheimer's Disease.
abstract: It is becoming more evident that histone acetylation, as one of the epigenetic modifications or markers, plays a key role in the etiology of Alzheimer's disease (AD). Histone acetylases and histone deacetylases (HDACs) are the well-known covalent enzymes that modify the reversible acetylation of lysine residues in histone amino-terminal domains. In AD, however, the roles of these enzymes are controversial. Some recent studies indicate that HDAC inhibitors are neuroprotective by regulating memory and synaptic dysfunctions in cellular and animal models of AD; while on the other hand, increase of histone acetylation have been implicated in AD pathology. In this review, we focus on the recent advances on the roles of histone acetylation covalent enzymes in AD and discuss how targeting these enzymes can ultimately lead to therapeutic approaches for treating AD.
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
authors.forename: Xi
authors.initials: X
authors.lastname: Lu
authors.affiliation: Department of Biotherapy and Hemato-oncology, Chongqing Cancer Institute , Chongqing , China.
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.affiliation: The Commonwealth Medical College , Scranton, PA , USA.
authors.forename: Caijia
authors.initials: C
authors.lastname: Yu
authors.affiliation: Department of Clinical Sciences, Temple Clinical Research Institute, Temple University School of Medicine , Philadelphia, PA , USA.
authors.forename: Daohai
authors.initials: D
authors.lastname: Yu
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
authors.forename: Gang
authors.initials: G
authors.lastname: Yu
keywords: Alzheimer’s disease; histone acetylase; histone acetylation; histone deacetylase; histone deacetylase inhibitor